A Phase 3 interventional study of Denosumab 60 MG [Prolia] and Placebo Injection in Bone Density, Bone Loss and Anorexia Nervosa, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-04.
Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing denosumab in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Denosumab · Bone Diseases, Metabolic.
Among the 25 studies testing denosumab in Bone Diseases, Metabolic, this one is the 22nd largest by enrollment, is the only one that started in 2017, is one of 13 in phase 3, and was the 18th registered.
662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.
Browse Bone Diseases, Metabolic studies →1 of the 25 studies testing denosumab in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18–100
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: 20 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 14 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 25 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,589 studies on the registry; 447 are open to participants now.
Of its 223 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
12 studies in Bone Diseases, Metabolic by Massachusetts General Hospital: none open now, none under way, none of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 12 studies in Bone Diseases, Metabolic by Massachusetts General Hospital, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 3, and was the 11th registered.
Massachusetts General Hospital’s Bone Diseases, Metabolic studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing denosumab in Bone Diseases, Metabolic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Massachusetts General Hospital’s 12 in Bone Diseases, Metabolic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to investigate the effect of denosumab on BMD in women with anorexia nervosa. The investigators hypothesize that 12 months of denosumab administration will result in an increase in bone mineral density, decrease in markers of bone resorption and improvement in bone microarchitecture in osteopenic women with anorexia nervosa compared with placebo.
An optional extension study will offer subjects 12-month administration of open-label alendronate (an oral bisphosphonate) after the initial 12 month administration of denosumab or placebo. We hypothesize that 12 months of denosumab followed by 12 months of open-label alendronate will result in a greater increase in BMD compared to 12 months of placebo followed by 12 months of open-label alendronate. Within the group of women who receive sequential therapy with 12 months of denosumab followed by 12 months of alendronate, we hypothesize that BMD will be maintained between 12 and 24 months while on alendronate.
Inclusion/Exclusion Criteria:
Inclusion Criteria:
For women of reproductive age, agree to use an effective method. Highly effective methods of birth control include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
Drug: Denosumab 60 MG [Prolia] · Drug: Alendronate 70Mg Tab
Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
Drug: Placebo Injection · Drug: Alendronate 70Mg Tab
Denosumab 60mg injection at baseline and 6 months
Placebo Injection at baseline and 6 months
Alendronate 70mg PO weekly starting at Month 12 through 24 months.
Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA)
Postero-anterior (PA) lumbar spine bone mineral density was assessed by dual-energy x-ray absorptiometry (DXA). The DXA scanner used was a Hologic Horizon A (Hologic, Inc., Waltham, MA).
Time frame: 12 months (Period 1)
Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
Time frame: Baseline to 24 months
Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
Time frame: 12 months to 24 months (Period 2)
Women, age 20-60 years, with anorexia nervosa or atypical anorexia nervosa and BMD T-score \< -1.0
| Milestone | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) |
|---|---|---|
| Started | 20 | 10 |
| Completed | 18 | 9 |
| Not completed | 2 | 1 |
| Withdrew: Relocation | 1 | 0 |
| Withdrew: Seeking higher level of care for eating disorder | 1 | 0 |
| Withdrew: Seeking treatment for chronic fatigue syndrome | 0 | 1 |
| Milestone | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) |
|---|---|---|
| Started | 18 | 9 |
| Completed | 15 | 6 |
| Not completed | 3 | 3 |
| Withdrew: Planning pregnancy | 2 | 2 |
| Withdrew: Personal reasons | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Postero-anterior (PA) lumbar spine bone mineral density was assessed by dual-energy x-ray absorptiometry (DXA). The DXA scanner used was a Hologic Horizon A (Hologic, Inc., Waltham, MA).
| g/cm^2 | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) |
|---|---|---|
| Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA) | 0.90 ± 0.03 | 0.87 ± 0.04 |
| % change | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) |
|---|---|---|
| Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA | 3.9 ± 4.3 | 5.8 ± 5.3 |
| % change | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) |
|---|---|---|
| Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA | -2.0 ± 3.7 | 4.6 ± 3.2 |
Collected over Baseline to 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab (0-12 months) followed by alendronate (12-24 months) | 0/20 (0%) | 0/20 (0%) | 6/20 (30%) |
| Placebo (0-12 months) followed by alendronate (12-24 months) | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) |
|---|---|---|
| constipationGastrointestinal disorders | 3/20 | 0/10 |
| COVID-19Infections and infestations | 1/20 | 1/10 |
| bone fractureInjury, poisoning and procedural complications | 1/20 | 1/10 |
| Gallbladder biliary dyskinesiaGastrointestinal disorders | 0/20 | 1/10 |
| nausea/stomach pain/bloatingGastrointestinal disorders | 1/20 | 0/10 |
| KeratitisInfections and infestations | 1/20 | 0/10 |
| C. difficileInfections and infestations | 1/20 | 0/10 |
| Disc degeneration and herniationInjury, poisoning and procedural complications | 1/20 | 0/10 |
Women, age 20-60 years, with anorexia nervosa or atypical anorexia nervosa and BMD T-score \< -1.0
| Age, Categorical(Participants) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 10 | 30 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| Mean | 29.2 ± 8.0 | 29.4 ± 6.8 | 29.3 ± 7.5 |
| Sex: Female, Male(Participants) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| Female | 20 | 10 | 30 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 20 | 10 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 19 | 10 | 29 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| United States | 20 | 10 | 30 |
| Body mass index (BMI)(kg / m^2) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| Mean | 19.0 ± 1.7 | 18.0 ± 2.0 | 18.7 ± 1.9 |
| Postero-anterior (PA) lumbar spine areal bone mineral density (aBMD) Z-score(Z-score) | Denosumab (0-12 months) followed by alendronate (12-24 months) | Placebo (0-12 months) followed by alendronate (12-24 months) | Total |
|---|---|---|---|
| Mean | -1.6 ± 0.9 | -1.7 ± 1.4 | -1.6 ± 1.1 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Jul 2021, 44 months.
Results were first posted in Oct 2022, 1 year 2 months after primary completion.
Of 26 phase 3 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 44 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Massachusetts General Hospital →